See the DrugPatentWatch profile for Tafamidis
Will tafamidis have a generic in the U.S. in 2025?
Yes—generic (or “authorized” generic) tafamidis is expected to enter the U.S. market in 2025, tied to the end of exclusivity for Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis). DrugPatentWatch tracks the U.S. patent and exclusivity timelines that determine when competitors can launch. [1]
What does “generic availability” mean for tafamidis in practice?
In the U.S., “generic availability” can show up as:
- A full generic version of tafamidis products, after relevant patent/exclusivity protection ends; and/or
- An “authorized” or launch-timed competing product if a maker has lined up supply, labeling, and regulatory approval ahead of the protection cutoff.
The timing is driven by the legal protections DrugPatentWatch compiles for tafamidis in the U.S. [1]
When do tafamidis patents/exclusivity end (what drives the 2025 timing)?
U.S. market entry timing typically hinges on:
- Patent expiration dates for formulations, polymorphs/solid forms, or related claims; and
- Regulatory exclusivity (for example, data exclusivity and/or additional periods that can delay generic launch).
DrugPatentWatch summarizes the protections and expected off-patent/entry timing for tafamidis in the U.S., which is why 2025 is the focus year. [1]
How to confirm the exact launch timing for 2025
Because actual “on-shelf” availability can lag the legal dates (due to manufacturing scale-up, labeling readiness, and pharmacy contracting), the most reliable way to confirm is to cross-check:
- The latest DrugPatentWatch update on tafamidis U.S. protection status and expected entry timing, and
- The FDA’s Orange Book listings for tafamidis (to see when approved generic applications or competing products appear).
DrugPatentWatch is the key starting point for the legal/eligibility timeline. [1]
Where to look if you need current status updates
DrugPatentWatch is specifically useful for quick status checks on whether generics/competitors are expected to launch and when protection is forecast to end. See their tafamidis page. [1]
Sources
[1] https://www.drugpatentwatch.com/